Focusing on specialty assets
Innovating Pharma
At Garda Therapeutics, our goal is to drive innovation in the pharmaceutical industry by maximizing opportunities with mid-sized specialty assets.
Our reason for being is to procure proprietary, “growable” therapeutic assets via product/company acquisitions or attractive licensing opportunities
Our comprehensive suite of professional services caters to a diverse clientele, ranging from homeowners to commercial developers.
Our reason for being is to procure proprietary, “growable” therapeutic assets via product/company acquisitions or attractive licensing opportunities
Our comprehensive suite of professional services caters to a diverse clientele, ranging from homeowners to commercial developers.
The market focus
We are an emerging pharmaceutical company dedicated to maximizing returns on mid-sized specialty assets while delivering high-quality treatments.
GARDA Therapeutics at a Glance
An emerging pharmaceutical company focusing on maximizing return on mid-sized specialty assets
-
• Senior management team shares 175+ years of collective experience in life sciences.
• Multiple product acquisitions with long track record of successfully growing underutilized, underappreciated therapeutics.
• Impressive value creation.
-
• Previous company experience in successfully acquiring and in-licensing assets.
• Most recent transactions (Secura Bio, Inc.) formed with the acquisition of FARYDAK® from Novartis in 2019.
• COPIKTRA® acquired from Verastem in 2020.
• Targeting potential assets in oncology, both hematology and solid tumors.
-
• Management experience in building teams customized to the special needs of individual assets… no “cookie-cutter” approaches
• Services are either internally staffed or managed via experienced external third-parties.
GARDA Management comes with:
A proven track record for optimizing asset growth in sophisticated specialty market
Expertise in clinical development for new indications for label expansion and/or publications
Repeated success in securing and capitalizing on assets with compelling revenue upside to create stakeholder value